(Q39979327)

16 September 2017

title

Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro (English)

1 reference

16 September 2017

0 references

Wei Pang

1

1 reference

16 September 2017

Rui-Rui Wang

2

1 reference

16 September 2017

Liu-Meng Yang

3

1 reference

16 September 2017

Chang-Mei Liu

4

1 reference

16 September 2017

Po Tien

5

1 reference

16 September 2017

Yong-Tang Zheng

6

1 reference

16 September 2017

language of work or name

English

0 references

publication date

22 May 2008

1 reference

16 September 2017

1 reference

16 September 2017

volume

377

1 reference

16 September 2017

issue

1

1 reference

16 September 2017

page(s)

80-87

1 reference

Inhibiting HIV-1 entry with fusion inhibitors

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Core structure of gp41 from the HIV envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

An update in the development of HIV entry inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Fusion inhibition--a major but costly step forward in the treatment of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Anti-HIV-1 property of trichosanthin correlates with its ribosome inactivating activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Zinc coupling potentiates anti-HIV-1 activity of baicalin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

The anti-HIV-1 effect of scutellarin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

Human immunodeficiency virus type 1 and 2 envelope glycoproteins oligomerize through conserved sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.04.013

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2008.04.013

1 reference

16 September 2017

1 reference